In a phase 1b trial of 145 patients with advanced NSCLC without the EGFR mutation or ALK fusion and not preselected for PDL-1 expression, improved response rates were seen with avelumab as first-line therapy (8). The gene discussed is CD274; the disease is non-small cell lung carcinoma.